An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening and disease modeling tools. The vascularized micro-tumor (VMT) is a novel three-dimensional model system (tumor-on-a-chip) that recapitulates the complex human tumor microenvironment, including perfused vasculature, within a transparent microfluidic device, allowing real-time study of drug responses and tumor-stromal interactions. Here we have validated this microphysiological system (MPS) platform for the study of colorectal cancer (CRC), the second leading cause of cancer-related deaths, by showing that gene expression, tumor heterogeneity, and treatment responses in the VMT more closely model CRC tumor clinicopathology than current standard drug screening modalities, including 2-dimensional monolayer culture and 3-dimensional spheroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to all of this, novel multicellular three-dimensional (3D) in vitro models can bridge the gap between experimental controllability and physiological relevance via reliably reproducing tissue or tumor architecture, mimicking tissue stiffness, allowing cellular crosstalk via the integration of multiple cell types and replicating various physical, morphological, structural, mechanical and”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Hachey et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, these physiologically relevant platforms have previously shown promise in drug discovery and testing by faithfully recapitulating pathophysiological human drug responses (Asghar et al., 2015; Benam et al., 2016; Hachey et al., 2021); hence offering the potential to advance the development of personalized therapy approaches.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Hachey et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, MPS models have been developed for the majority of human tissues and organs, and have also been established to study a diverse range of malignancies, including cancer (Baptista et al., 2022; Hachey et al. (2021; 2024); Jiang et al., 2024; Haque et al., 2022; Shen et al., 2023; Flont et al., 2023; Straehla et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Hachey et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The model has been adapted to multiple cancer types, including immunologically ‘cold’ or ‘mixed’ tumors such as breast cancer, MSS subtype colorectal cancer and ovarian cancer, which display varying degrees of vascular disruption (Jahid et al., 2022; Hachey et al., 2024), Hachey et al. (2021)).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Hachey et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumor chips have been developed to model a broad variety of cancers, including primary lung cancer, prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, melanoma, liver cancer and glioblastoma (among other cancers), as well as cancer metastasis to the bone, the brain, the liver and the lung (Hachey et al. (2021; 2024); Jiang et al. (2024); Haque et al. (2022); Shen et al. (2023);”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Hachey et al., 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N. J., Livak, K. J., Mikkelsen, T. S., & Rinn, J. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2859 · Cited by 7,314
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Self-citationMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Research works printed but not linked: 4
- RStudio Team, RStudio: Integrated Development Environment for R, RStudio, Inc., Boston, MA, 2016
- 10XGenomics, Vartrix single-cell genotyping tool
- Tickle T., Tirosh I., Georgescu C., Brown M. and Haas B., inferCNV of the Trinity CTAT Project, Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA, 2019
- Sharma G. and Stein-O'Brien G., projectR: Functions for the projection of weights from PCA, CoGAPS, NMF, correlation, and clustering, 2016
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
“To date, numerous researchers have developed their own organoids-on-chip systems 145,147 – 149 , whereas others have used commercially available chips 150,151 .”
BackgroundEngineering Vascularized Organoid-on-a-Chip Models
Shirure, V. S., Hughes, C. C. W., & George, S. C. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-090120-094330 · Cited by 193
Tumor-on-chip modeling of organ-specific cancer and metastasis
Del Piccolo, N., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 126
Organ-on-a-chip systems for vascular biology
Mandrycky, C., Howard, C. C., Rayner, S. G., Shin, Y. J., & Zheng, Y. Y. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.06.002 · Cited by 107
Intestinal organ chips for disease modelling and personalized medicine
Özkan, A., LoGrande, N., Feitor, J. F., Goyal, G., & Ingber, D. E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00968-3 · Cited by 110
“Transcriptomic analysis of the HCT116 CRC cell line cultured within self-assembled microvascular capillaries and with fibroblasts under dynamic fluid flow revealed expression of cancer-related genes similar to xenograft tumours, which could not be reca-pitulated in 2D culture 146 .”
Zhu, J., Ji, L., Chen, Y., Li, H., Huang, M., Dai, Z., Wang, J., Xiang, D., Fu, G., Lei, Z., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01354-9 · Cited by 95
“Vascularized micro-tumors HCT116, SW480 ECs, matrix and fibroblasts PDMS 3-layered channels Soft lithography Direct exchange [78]”
BackgroundMethodInfluentialNew Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay
Wan, Z., Floryan, M. A., Coughlin, M. F., Zhang, S., Zhong, A. X., Shelton, S. E., Wang, X., Xu, C., Barbie, D. A., & Kamm, R. D. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202201784 · Cited by 84
Strelez, C., Chilakala, S., Ghaffarian, K., Lau, R., Spiller, E. R., Ung, N. M., Hixon, D., Yoon, A. Y., Sun, R., Lenz, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102509 · Cited by 92
Emerging tumor-on-chips with electrochemical biosensors
Lei, L., Ma, B., Xu, C., & Liu, H. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116640 · Cited by 72
Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues
Hwangbo, H., Chae, S., Kim, W.-J., Jo, S., & Kim, G. (2023) · Theranostics · doi:10.7150/thno.90093 · Cited by 74
Recent Advances of Organ-on-a-Chip in Cancer Modeling Research
Liu, X., Su, Q., Zhang, X., Yang, W., Ning, J., Jia, K., Xin, J., Li, H., Yu, L., Liao, Y., et al. (2022) · Biosensors · doi:10.3390/bios12111045 · Cited by 76
Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Jouybar, M., de Winde, C. M., Wolf, K., Friedl, P., Mebius, R. E., & den Toonder, J. M. J. (2024) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.10.001 · Cited by 66
“In a self-assembly model of vascularized human colorectal cancer, irregular, leaky, and ill-perfused microvasculature was observed to form within the tumor, a typical phenomenon for cancer microvasculature (Figure 3C) [59].”
BackgroundOrganoids/organs-on-a-chip: new frontiers of intestinal pathophysiological models
Wu, L., Ai, Y., Xie, R., Xiong, J., Wang, Y., & Liang, Q. (2023) · Lab on a Chip · doi:10.1039/d2lc00804a · Cited by 69
Sunildutt, N., Parihar, P., Salih, A. R. C., Lee, S. H., & Choi, K. H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1139229 · Cited by 71
“Validation of this model was achieved through biomarker expression, including ANGPT2, NID2, APLN, CYTL1, DLL4, and IGFBP4 (Hachey et al., 2021).”
MethodInfluentialIbrahim, L. I., Hajal, C., Offeddu, G. S., Gillrie, M. R., & Kamm, R. D. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121728 · Cited by 53
Fluid flow to mimic organ function in 3D in vitro models
Juste-Lanas, Y., Hervás-Raluy, S., García‐Aznar, J. M., & González‐Loyola, A. (2023) · APL Bioengineering · doi:10.1063/5.0146000 · Cited by 57
Engineering Organ-on-a-Chip to Accelerate Translational Research
Ko, J., Park, D., Lee, S., Gümüşcü, B., & Jeon, N. L. (2022) · Micromachines · doi:10.3390/mi13081200 · Cited by 59
“Tumor growth was significantly reduced in-vitro compared to the control “placebo” group [64].”
BackgroundOrganoids‐On‐a‐Chip for Personalized Precision Medicine
Man, Y., Liu, Y., Chen, Q., Zhang, Z., Li, M., Xu, L., Tan, Y., & Liu, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401843 · Cited by 58
Liu, Y., Sakolish, C., Chen, Z., Phan, D. T. T., Bender, R. H. F., Hughes, C. C. W., & Rusyn, I. (2020) · Toxicology · doi:10.1016/j.tox.2020.152601 · Cited by 49
Al-Kabani, A., Huda, B., Haddad, J., Yousuf, M., Bhurka, F., Ajaz, F., Patnaik, R., Jannati, S., & Banerjee, Y. (2025) · Cancers · doi:10.3390/cancers17132163 · Cited by 57
Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics
Hammel, J. H., Zatorski, J. M., Cook, S. R., Pompano, R. R., & Munson, J. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114111 · Cited by 44
Bender, R. H. F., O’Donnell, B. T., Shergill, B. S., Pham, B. Q., Tahmouresie, S., Sanchez, C. N., Juat, D. J., Hatch, M. M. S., Shirure, V. S., Wortham, M., et al. (2023) · Biofabrication · doi:10.1088/1758-5090/ad17d0 · Cited by 49
Chen, M., Choi, H. K., Goldston, L. L., Hou, Y., Jiang, C., & Lee, K. (2025) · ACS Nano · doi:10.1021/acsnano.5c06940 · Cited by 48
Nguyen, H. T., Kan, E. L., Humayun, M., Gurvich, N., Offeddu, G. S., Wan, Z., Coughlin, M. F., Renteria, D. C., Loew, A., Wilson, S. D., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2024.122731 · Cited by 49
Cancer-on-chip: a 3D model for the study of the tumor microenvironment
Cauli, E., Polidoro, M. A., Marzorati, S., Bernardi, C., Rasponi, M., & Lleò, A. (2023) · Journal of Biological Engineering · doi:10.1186/s13036-023-00372-6 · Cited by 52
Siddiqui, M. F., Jabeen, S., Alwazzan, A., Vacca, S., Dalal, L., Al-Haddad, B., Jaber, A., Ballout, F. F., Zeid, H. K. A., Haydamous, J., et al. (2025) · Journal of Medical Education and Curricular Development · doi:10.1177/23821205251342315 · Cited by 70
“25 The use of XR technology in medical education, speci fi c-ally HMDs, provides an immersive and interactive experience that combines physical objects with computer-generated elements.”
The vascular niche in next generation microphysiological systems
Ewald, M. L., Chen, Y.-H., Lee, A. P., & Hughes, C. C. W. (2021) · Lab on a Chip · doi:10.1039/d1lc00530h · Cited by 43
Tissue‐Engineered Microvessels: A Review of Current Engineering Strategies and Applications
Zhao, N., Pessell, A. F., Zhu, N., & Searson, P. C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303419 · Cited by 43
Vascularized organoid-on-a-chip: design, imaging, and analysis
Yu, T., Yang, Q., Peng, B., Gu, Z., & Zhu, D. Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09905-z · Cited by 37
On-chip modeling of tumor evolution: Advances, challenges and opportunities
Li, C., Holman, J. B., Shi, Z., Qiu, B., & Ding, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100724 · Cited by 39
Wu, Y., Zhou, Y., Qin, X., & Liu, Y. (2021) · Biomicrofluidics · doi:10.1063/5.0062697 · Cited by 38
Organ-on-Chip platforms to study tumor evolution and chemosensitivity
Dsouza, V. L., Kuthethur, R., Kabekkodu, S. P., & Chakrabarty, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188717 · Cited by 39
Hachey, S. J., Sobrino, A., Lee, J. G., Jafari, M. D., Klempner, S. J., Puttock, E. J., Edwards, R. A., Lowengrub, J. S., Waterman, M. L., Zell, J. A., et al. (2022) · Translational research · doi:10.1016/j.trsl.2022.11.011 · Cited by 35
“15 Briefly, polydimethylsiloxane (PDMS, Sigma-Aldrich) is poured into a customized polyurethane master mold of the VMT device design and allowed to polymerize overnight in a 70°C oven.”
BackgroundMethodInfluentialThree-dimensional heterotypic colorectal cancer spheroid models for evaluation of drug response
Yau, J. N. N., & Adriani, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1148930 · Cited by 33
“While vascularized heterotypic CRC spheroids will indeed represent a pathophysiologically relevant TME for drug screening (95) and studying the permeation of drugs through vasculature (96), few vascularized CRC models (97, 98) have been presented.”
BackgroundThe Versatility and Diagnostic Potential of VOC Profiling for Noninfectious Diseases
Oxner, M., Trang, A., Mehta, J., Forsyth, C. B., Swanson, B. A., Keshavarzian, A., & Bhushan, A. (2023) · BME Frontiers · doi:10.34133/bmef.0002 · Cited by 35
Wang, R., Zhang, C., Li, D., & Yao, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1057913 · Cited by 33
Engineering Mesoscopic 3D Tumor Models with a Self‐Organizing Vascularized Matrix
Lorenzi, F. D., Hansen, N., Theek, B., Daware, R., Motta, A., Breuel, S., Nasehi, R., Baumeister, J., Schöneberg, J., Stojanovic, N. M., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303196 · Cited by 43
Preclinical Testing Techniques: Paving the Way for New Oncology Screening Approaches
van Rijt, A., Stefanek, E., & Valente, K. P. (2023) · Cancers · doi:10.3390/cancers15184466 · Cited by 32
Trigt, W. K. V., Kelly, K. M., & Hughes, C. C. W. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.1006027 · Cited by 34
“and others have demonstrated the utility of these platforms for screening novel and repurposed therapeutics (Sobrino et al., 2016; Phan et al., 2017; Liu et al., 2020; Hachey et al., 2021).”
BackgroundSpheroids and organoids derived from colorectal cancer as tools for in vitro drug screening
Zawawi, S. S. A., Salleh, E. A., & Musa, M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00226 · Cited by 27
Park, D., Lee, J., Lee, Y., Son, K., Choi, J. W., Jeang, W. J., Choi, H., Hwang, Y., Kim, H., & Jeon, N. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-99387-6 · Cited by 29
Hachey, S. J., Hatch, C. J., Gaebler, D., Mocherla, A., Nee, K., Kessenbrock, K., & Hughes, C. C. W. (2024) · Breast Cancer Research · doi:10.1186/s13058-023-01760-y · Cited by 24
“Device fabrication and loading has been described previously [13, 14, 16, 17, 57].”
BackgroundSelf-citationPoggi, A. D., Villa, F., Fernandez, J. L. C., Costa, D., Zocchi, M. R., & Benelli, R. (2021) · Cancers · doi:10.3390/cancers13143417 · Cited by 27
Engineering a Vascularized Hypoxic Tumor Model for Therapeutic Assessment
Ando, Y., Oh, J. M., Zhao, W., Tran, M., & Shen, K. (2021) · Cells · doi:10.3390/cells10092201 · Cited by 25
Sánchez-Salazar, M. G., Oliver, R. C.-L., Ramos-Meizoso, S., Jerezano-Flores, V. S., Gallegos-Martínez, S., Bolívar‐Monsalve, E. J., Ceballos‐González, C. F., Santiago, G. T., & Álvarez, M. M. (2023) · Bioengineering · doi:10.3390/bioengineering10050554 · Cited by 26
“In the literature, rectangular [1,18,23], circular [6,27,28], and rhomboidal [9,29] shapes are frequently used for the fabrication of ToCs.”
BackgroundUse and application of organ-on-a-chip platforms in cancer research
Yu, Y., Zhou, T., & Cao, L.-L. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00790-7 · Cited by 31
Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift
Lopez-Vince, E., Wilhelm, C., & Simón‐Yarza, T. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01580-3 · Cited by 26
Martier, A. T., Chen, Z., Schaps, H., Mondrinos, M. J., & Fang, J. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1425618 · Cited by 25
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
Jahid, S., Ortega, J. A., Vuong, L. M., Acquistapace, I. M., Hachey, S. J., Flesher, J. L., La Serra, M. A., Brindani, N., La Sala, G., Manigrasso, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110641 · Cited by 21
Self-citationMimicking and surpassing the xenograft model with cancer-on-chip technology
Komen, J., van Neerven, S. M., van den Berg, A., Vermeulen, L., & van der Meer, A. D. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103303 · Cited by 24
“The vessels provide nutrients and drugs to cancer cell clusters embedded in extracellular matrix containing fibroblasts [81].”
BackgroundAdvancements in 3D In Vitro Models for Colorectal Cancer
Vitale, S., Calapà, F., Colonna, F., Luongo, F., Biffoni, M., Maria, R. D., & Fiori, M. E. (2024) · Advanced Science · doi:10.1002/advs.202405084 · Cited by 23
Recent advances in cancer-on-a-chip tissue models to dissect the tumour microenvironment
Seaman, K., Sun, Y., & You, L. (2023) · Med-X · doi:10.1007/s44258-023-00011-1 · Cited by 26
“Tumours derived from the VMT model contained a distinct neural/glial antigen 2-positive (NG2 +) population that underwent the epithelial to mesenchymal transition (EMT), whereas cancer cells in 2D and 3D monocultures did not [95].”
BackgroundMethodInfluentialRevealing the clinical potential of high-resolution organoids
Ko, J., Hyung, S., Cheong, S., Chung, Y., & Jeon, N. L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115202 · Cited by 24
Engineered Vasculature for Cancer Research and Regenerative Medicine
Nguyen, H. T., Peirsman, A., Tirpáková, Z., Mandal, K., Vanlauwe, F., Maity, S., Kawakita, S., Khorsandi, D., Herculano, R. D., Umemura, C., et al. (2023) · Micromachines · doi:10.3390/mi14050978 · Cited by 19
“, which developed a 3D tumor model on a chip to simulate a human tumor microenvironment [87].”
BackgroundResultGaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1462293 · Cited by 22
In Vitro Models of Blood and Lymphatic Vessels—Connecting Tissues and Immunity
Bogseth, A., Ramirez, A., Vaughan, E., & Maisel, K. (2022) · Advanced Biology · doi:10.1002/adbi.202200041 · Cited by 20
Bourn, M. D., Mohajerani, S. Z., Mavria, G., Ingram, N., Coletta, P. L., Evans, S. D., & Peyman, S. A. (2023) · Lab on a Chip · doi:10.1039/d2lc00963c · Cited by 20
Engineering high throughput screening platforms of cervical cancer
Cadena, I., Buchanan, M. R., Harris, C. G., Jenne, M., Rochefort, W. E., Nelson, D., & Fogg, K. C. (2023) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37522 · Cited by 16
Siddiqui, M. F., Mouna, A., Nicolas, G. N., Rahat, S. A. A., Nurmamatovna, M. A., Emmanuel, N., & Tashmatova, N. M. (2022) · Studies in computational intelligence · doi:10.1007/978-981-16-9221-5_14 · Cited by 17
Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics
Hu, J., Liu, K., Ghosh, C., Khaket, T. P., Shih, H. A., & Kebebew, E. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03009-8 · Cited by 17
“Although this is the first time this has been reported in ATC tumor spheroids, better recapitulations of tumor conditions in 3D than in 2D models from the transcriptional landscape were also discovered in the modeling of other cancer diseases [52–54].”
BackgroundVascular microphysiological systems (MPS): biologically relevant and potent models
Breuil, L., Kitada, A., Yadav, S., Zhou, H., Fujimoto, K., & Yokokawa, R. (2025) · Lab on a Chip · doi:10.1039/d5lc00014a · Cited by 19
Poljak, I., Chiappini, C., & Adriani, G. (2026) · Lab on a Chip · doi:10.1039/d5lc01060h · Cited by 17
Gallegos-Martínez, S., Buentello, D. C., Pérez-Álvarez, K. A., Lara-Mayorga, I. M., Aceves-Colin, A. E., Zhang, Y. S., Santiago, G. T., & Álvarez, M. M. (2024) · Biofabrication · doi:10.1088/1758-5090/ad5765 · Cited by 16
“At present, traditional 2D models are extensively used in cancer research; however, they do not fully recapitulate key physiological aspects of real tumors, such as the 3D tumor architecture, gene expression profiles, cell-interactions, and chemical gradients [2–5].”
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Lee, S., Kim, S., & Jeon, J. S. (2022) · Lab on a Chip · doi:10.1039/d2lc00672c · Cited by 14
Liu, X., Shu, Y., Zhu, J., Fang, H., Su, Y., Ma, H., Li, B., Xu, J., Cheng, Y. Y., Pan, B., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139346 · Cited by 16
Recapitulating the Cancer Microenvironment Using Bioprinting Technology for Precision Medicine
Kim, J., Jang, J., & Cho, D. (2021) · Micromachines · doi:10.3390/mi12091122 · Cited by 13
How inclusive are cell lines in preclinical engineered cancer models?
Raghavan, S. A. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049520 · Cited by 14
Konopka, J., Żuchowska, A., & Jastrzębska, E. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115986 · Cited by 11
Recent advances and future prospects of functional organ-on-a-chip systems
Moghaddam, A. S., Moghaddam, Z. S., Davachi, S. M., Sarikhani, E., Mahand, S. N., Khonakdar, H. A., Bagher, Z., & Ashammakhi, N. A. (2022) · Materials Chemistry Frontiers · doi:10.1039/d2qm00072e · Cited by 9
Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research
Hachey, S. J., Gaebler, D., & Hughes, C. C. W. (2023) · Journal of Visualized Experiments · doi:10.3791/65865 · Cited by 12
Phillips, C. M., Lima, E. A. B. F., Gadde, M., Jarrett, A. M., Rylander, M. N., & Yankeelov, T. E. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009499 · Cited by 10
Parihar, P., Sunildutt, N., Rahim, C. S. A., Samantasinghar, A., Lim, J., & Choi, K. H. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202300410 · Cited by 10
Mazzaglia, C., Huang, Y. Y. S., & Shields, J. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115485 · Cited by 10
Cellular Systems for Colorectal Stem Cancer Cell Research
Grigoreva, T. A., Kindt, D. N., Sagaidak, A. V., Novikova, D., & Tribulovich, V. G. (2025) · Cells · doi:10.3390/cells14030170 · Cited by 8
“These systems are significantly more complex than the approaches described above, but they allow for the reproduction of biochemical and biophysical conditions, including vascularization [155–159].”
Engineering tumor spatial heterogeneity in vitro
Chen, C., Zhao, Z., Seah, D. H., Wu, K. Z., Mohanaselvi, S., & Fong, E. L. S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115757 · Cited by 14
From Spheroids to Tumor-on-a-Chip for Cancer Modeling and Therapeutic Testing
Lipreri, M. V., Totaro, M. T., Baldini, N., & Avnet, S. (2025) · Micromachines · doi:10.3390/mi16121343 · Cited by 10
Advances and Applications of Organ-on-a-Chip and Tissue-on-a-Chip Technology
Moore, M., Sriram, S., Ku, J. C., & Li, Y. (2025) · Bioengineering · doi:10.3390/bioengineering13010009 · Cited by 10
Hanitrarimalala, V., Prgomet, Z., Hedhammar, M., Tassidis, H., & Wingren, A. G. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1545017 · Cited by 10
Komen, J., van Neerven, S. M., Bossink, E. G. B. M., de Groot, N. E., Nijman, L. E., van den Berg, A., Vermeulen, L., & van der Meer, A. D. (2022) · Micromachines · doi:10.3390/mi13050739 · Cited by 8
“These first studies were based on cancer-on-chip models that included vascularization, stromal cell coculture [18,19], patient-derived cells [16], and dynamic drug concentrations [17].”
BackgroundMethods for processing and analyzing images of vascularized micro-organ and tumor systems
Hachey, S. J., Hatch, C. J., Gaebler, D., Forsythe, A. G., Ewald, M. L., Chopra, A. L., Chen, Z., Thapa, K., Hodanu, M., Fang, J. S., et al. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1585003 · Cited by 5
“Some, like MDA-MB-231 breast cancer cells, show invasive, diffuse growth, while others form compact nodular masses (Hachey et al., 2021; 2024).”
InfluentialGoto, A., Moriya, Y., Nakayama, M., Iwasaki, S., & Yamamoto, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101003 · Cited by 5
Topological data analysis of pattern formation of human induced pluripotent stem cell colonies
Hartsock, I., Park, E., Toppen, J., Bubenik, P., Dimitrova, E., Kemp, M. L., & Cruz, D. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-90592-1 · Cited by 11
Randall‐Demllo, S., Al-Qadami, G. H., Raposo, A. E., Ma, C., Priebe, I. K., Hor, M., Singh, R., & Fung, K. Y. C. (2024) · Cancers · doi:10.3390/cancers16213664 · Cited by 6
“The vasculature model showed similar drug sensitivity to xenograft tumours (1.12 ± 0.01 vs. 1.19 ± 0.27 fold change reduction in tumour size), but significantly different responses to the 2D monolayer culture, which experienced a 96% reduction in cell number [67].”
BackgroundInfluentialZhang, S., Wan, Z., Wang, L., Wu, C., Zhang, J., Spitz, S., Wang, X. S., Floryan, M. A., Coughlin, M. F., Pramotton, F. M., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504849 · Cited by 7
Hsu, Y., Yang, W.-C., Chen, Y.-T., Lin, C.-Y., Yang, C.-F., Liu, W., Shivani, S., & Li, P. (2024) · Lab on a Chip · doi:10.1039/d3lc00891f · Cited by 3
Ibrahim, R. S., El‐Wadood, H. M. A., El‐Zahry, M. R., & Hosny, N. M. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113137 · Cited by 4
The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research
Grigoreva, T. A., Kindt, D. N., Sagaidak, A. V., Romanova, A. A., & Tribulovich, V. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110400 · Cited by 3
Using biomaterial-based 3D in vitro cancer models to solve current clinical problems
Tipple, E. F., Slay, E., Tsigkou, O., Choudhury, A., & Gough, J. E. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03392-3 · Cited by 5
“The utilisation of biomaterials in 3D in vitro modelling of tumours allows the fabrication of a variety of cancer models, including lung, breast, ovarian, bladder, and colorectal cancers [50, 64, 80 – 83].”
Lampejo, A. O., Lightsey, S. E., Gomes, M. C., Nguyen, C. M., Siemann, D. W., Sharma, B., & Murfee, W. L. (2024) · Annals of Biomedical Engineering · doi:10.1007/s10439-024-03535-8 · Cited by 5
“…glioblastoma, breast, hepatic, kidney, colorectal, and melanoma cell lines have all been incorporated into microfluidic devices and vascularized, resulting in fundamental advances in our understanding of tumor growth and the microvascular interactions that occur between tumors and vessels [28–35].”
Munoz, J. M., Pileggi, G. F., Nucci, M. P., Alves, A. H., Pedrini, F., Valle, N. M. E., Mamani, J. B., Oliveira, F. A., Lopes, A. T., Carreño, M. N. P., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091156 · Cited by 8
A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular LesionsPreprint
Fang, J. S., Hatch, C. J., Andrejecsk, J. W., Trigt, W. K. V., Juat, D. J., Chen, Y., Matsumoto, S., Lee, A. P., & Hughes, C. C. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.11.584490 · Cited by 3
“28,29,31,35 Once vessel formation was complete, addition of 70kDa fluorescent dextran to the media reservoirs marked lumenized microvessels and revealed that vessels are perfused and that flow is only through vessels ( Figure 2D ).”
BackgroundMethodJouybar, M., van der Kallen, S., Moradi, H., Zuo, P., Stassen, O. M. J. A., & den Toonder, J. M. J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101926 · Cited by 6
Vuong, L. M., Hachey, S. J., Shiu, J., Xie, D. F., Salvador, N., Brindani, N., Bertozzi, S. M., Summa, M., Bertorelli, R., Armirotti, A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112971 · Cited by 2
Functional vasculature in tumor organoids: Enabling precision medicine in oncology
Wu, W., Yao, G., Liu, Y., Zhang, L., Li, Z., Feng, X., Tao, S., Song, J., Kong, T., & Zhou, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189597 · Cited by 4
Li, Y., Cao, Z., Xu, Y., Li, C., Ye, S., Wu, X., Wang, Z., Chen, H., Liu, H., Hu, X., et al. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01244-x · Cited by 4
“By encapsulating cells within precisely de fi ned droplets or microwell arrays, these systems offer exceptional control over spheroid size, cell density, and matrix composition 23 , enabling automated drug screening 24 and complex disease modeling 25 .”
Dormancy in Metastatic Colorectal Cancer: Tissue Engineering Opportunities for In Vitro Modeling
VandenHeuvel, S. N., Nash, L. L., & Raghavan, S. A. (2025) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2025.0009 · Cited by 4
A microphysiological system HHT-on-a-chip platform recapitulates patient vascular lesions
Fang, J. S., Hatch, C. J., Andrejecsk, J. W., Trigt, W. K. V., Gonzales, J. R., Juat, D. J., Looker, E. K., Harris, S. R., Chen, Y., Matsumoto, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76448-w · Cited by 6
“We seeded EC transfected with si-ACVRL1 (or non-targeting si-Ctrl) into our previously described VMO platform 31,32,34,38 at equal starting cell densities (Supplementary Fig.”
Angiogenesis: Biological Mechanisms and In Vitro Models
Brunmaier, L. A. E., Özdemir, T., & Walker, T. W. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03721-2 · Cited by 1
“In vitro models of the vascular system generally involve the culturing of ECs in a hydrogel 3D channel, then introducing different signaling factors (angiogenic factors) to induce EC sprouting from the cultured channel and to form a small web-like vascular structure within the hydrogel [16–20].”
Influential
Metadata
- Authors
- Hachey, S. J., Movsesyan, S., Nguyen, Q. H., Burton-Sojo, G., Tankazyan, A., Wu, J., Hoang, T., Zhao, D., Wang, S., Hatch, M. M., Celaya, E., Gomez, S., Chen, G. T., Davis, R. T., Nee, K., Pervolarakis, N., Lawson, D. A., Kessenbrock, K., Lee, A. P., Lowengrub, J., Waterman, M. L., & Hughes, C. C. W.
- Affiliations
- University of California, Irvine (US)
- Department of Molecular Biology and Biochemistry
- Corresponding author
- Hughes, Christopher C. W.
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 21
- Issue
- 7
- Pages
- 1333-1351
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- PMC
- PMC8525497
- OpenAlex
- W3130617653
- Cited by
- 124
- References
- 50
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 30 · 2023: 24 · 2022: 18 · 2021: 11
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Lab on a Chip (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Edwards Lifesciences
- Chao Family Comprehensive Cancer Center (P30A062203)
- National Institutes of Health (CA217378, CA180122, TR-000481)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Keywords
- colorectal cancer, tumor-on-a-chip, microphysiological systems, microfluidics, tumor microenvironment, drug screening, tumor heterogeneity, tumor-stroma interactions, preclinical model validation, multicellular spheroids, gene expression
- MeSH terms
- Antineoplastic Agents, Drug Evaluation, Preclinical, Humans, Colorectal Neoplasms, Lab-On-A-Chip Devices, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.